Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
The Citizen2d
Tanzania hosts 11th Merck Foundation Africa-Asia Luminary
The event will pave the way for new commitments from First Ladies, ministers, and the Merck Foundation team to create more ...
kalkinemedia3d
Merck (MRK): Wall Street's Positive Sentiment and What It Means
Headlines,Wall Street analysts show strong enthusiasm for Merck, (NYSE:MRK),, with the average brokerage recommendation (ABR) ...
Le Lézard5d
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
In its Phase 3 trial conducted in China, Ivonescimab shattered expectations, reducing the risk of disease progression or death by 49% compared to Merck's Keytruda (pembrolizumab). With a nearly ...
GlobalData on MSN5d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...